<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622284</url>
  </required_header>
  <id_info>
    <org_study_id>1218.20</org_study_id>
    <secondary_id>2007-004585-40</secondary_id>
    <nct_id>NCT00622284</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and tolerability of
      BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to
      preferably &gt; 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient
      glycaemic control
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline at Week 52</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c Change From Baseline at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
    <description>This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline at Week 52</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
    <description>This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycaemic Events up to 52 Weeks</measure>
    <time_frame>Week 52</time_frame>
    <description>A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycaemic Events up to 104 Weeks</measure>
    <time_frame>Week 104</time_frame>
    <description>A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline at Week 52</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
    <description>This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7.0% at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c &gt;= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c &gt;= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7.0% at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c &gt;= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c &gt;= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;6.5% at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c &gt;= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c &gt;= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;6.5% at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c &gt;= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c &gt;= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c Lowering by 0.5% at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
    <description>This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 4</measure>
    <time_frame>Baseline and week 4</time_frame>
    <description>Difference of base percent value [Week x(%) - baseline (%)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 12</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 16</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 28</measure>
    <time_frame>Baseline and week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 40</measure>
    <time_frame>Baseline and week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 52</measure>
    <time_frame>Baseline and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 65</measure>
    <time_frame>Baseline and week 65</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 78</measure>
    <time_frame>Baseline and week 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 91</measure>
    <time_frame>Baseline and week 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
    <description>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Lipid Parameter Cholesterol at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Lipid Parameter HDL at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline Lipid Parameter Triglyceride at Week 104</measure>
    <time_frame>Baseline and week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1560</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 1356 5mg, once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to BI 1356 5mg</intervention_name>
    <description>Placebo tablet once daily</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg</intervention_name>
    <description>Placebo tablets once daily</description>
    <arm_group_label>BI 1356 5mg, once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1356</intervention_name>
    <description>5mg, once daily in the morning for 104 weeks</description>
    <arm_group_label>BI 1356 5mg, once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>1mg or 2mg or 3mg or 4mg in the morning for 104 weeks</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously
             treated with metformin alone or with metformin and one other oral antidiabetic drug

          2. Glycosylated haemoglobin (HbA1c) 6.0 - 9.0% at screening for patients treated with
             metformin and one other oral antidiabetic drug

          3. HbA1c 6.5 - 10.0% at screening for patients treated with metformin alone

          4. HbA1c 6.5 - 10.0% at beginning of the placebo run-in phase

        Exclusion criteria:

          1. Myocardial infarction, stroke or transient ischemic attack (TIA)

          2. Impaired hepatic function

          3. Renal failure or renal impairment

          4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening

          5. Treatment with insulin or glucagon-like peptide 1 (GLP-1) analogue/antagonists within
             3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.20.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.10026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3307I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3310B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3310C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3310D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3310E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3312B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3312C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3312D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3308D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3308E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3308F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3309B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3309C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3309D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3309E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3311A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3311B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3311C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3313A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3313B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3313C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3313D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3314A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3314B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3314C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3314D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3314E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3314F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joué les Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3302I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3303I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3304C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3304D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3304F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3304H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3305H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3306I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.3311D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Potigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Mergentheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Flörsheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großheirath</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haag</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hatten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelkheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Künzing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saaldorf-Surheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Speyer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingbert/Oberwürzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westerkappeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.85202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.85204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ajka</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hódmezövásárhely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Makó</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.36203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szentes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gujarat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kochi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patna</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.91026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamilnadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Codogno (lo)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.39020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beek en Donk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ewijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogwoud</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oude Pekela</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rilland</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roelofarendsveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wildervank</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fevik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fornebu</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>RUD</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.48209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baillieston, Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cheadle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chestfield, Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ely</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.20.44107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <results_first_submitted>November 30, 2011</results_first_submitted>
  <results_first_submitted_qc>January 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2012</results_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were in total 1560 patients randomised in the study. Of these, 1 patient was not treated. The remaining 8 patients not accounted for in the treated set were removed from all study analyses (explained in trial report) due to major good-clinical-practice violations at the site, and the inability to verify the validity of any patient level data.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin</title>
          <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
        </group>
        <group group_id="P2">
          <title>Glimepiride</title>
          <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="776">Number who started treatment. One patient in the Linagliptin group was randomized but not treated.</participants>
                <participants group_id="P2" count="775">Number who started treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="587">Number who completed treatment.</participants>
                <participants group_id="P2" count="604">Number who completed treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin</title>
          <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
        </group>
        <group group_id="B2">
          <title>Glimepiride</title>
          <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="776"/>
            <count group_id="B2" value="775"/>
            <count group_id="B3" value="1551"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.8" spread="9.4"/>
                    <measurement group_id="B2" value="59.8" spread="9.4"/>
                    <measurement group_id="B3" value="59.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="462"/>
                    <measurement group_id="B2" value="471"/>
                    <measurement group_id="B3" value="933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI) continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.21" spread="4.77"/>
                    <measurement group_id="B2" value="30.31" spread="4.57"/>
                    <measurement group_id="B3" value="30.26" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.14" spread="17.57"/>
                    <measurement group_id="B2" value="86.77" spread="16.69"/>
                    <measurement group_id="B3" value="86.46" spread="17.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated haemoglobin (HbA1c)</title>
          <description>Baseline HbA1c was available for 1519 patients in the Full Analysis Set (FAS), 764 treated with Linagliptin and 755 patients treated with Glimepiride.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.69" spread="0.88"/>
                    <measurement group_id="B2" value="7.69" spread="0.86"/>
                    <measurement group_id="B3" value="7.69" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting blood plasma glucose (FPG)</title>
          <description>Baseline fasting plasma glucose (FPG) was available for 1475 patients in the FAS, 740 treated with Linagliptin and 735 patients treated with Glimepiride.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.46" spread="42.83"/>
                    <measurement group_id="B2" value="166.09" spread="42.05"/>
                    <measurement group_id="B3" value="165.27" spread="42.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline at Week 52</title>
        <description>This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 52</title>
          <description>This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.03"/>
                    <measurement group_id="O2" value="-0.57" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis of non-inferiority is rejected if the upper bound of the two-sided 97.5% confidence interval is less than 0.35%. Superiority testing was not part of the pre-specified Week 52 confirmatory analysis.</non_inferiority_desc>
            <p_value>0.0005</p_value>
            <p_value_desc>Due to multiple testing of the primary endpoints at weeks 52 and 104 a Bonferroni correction was applied and 97.5% confidence intervals produced. This 1-sided p-value for non-inferiority should be compared to the 1-sided threshold of 0.0125.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline at Week 104</title>
        <description>This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</description>
        <time_frame>Baseline and week 104</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 104</title>
          <description>This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.03"/>
                    <measurement group_id="O2" value="-0.36" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The null hypothesis of non-inferiority is rejected if the upper bound of the two-sided 97.5% confidence interval is less than 0.35%. However, superiority testing is only applicable if the Linagliptin decrease is greater than that in Glimepiride.</non_inferiority_desc>
            <p_value>0.0004</p_value>
            <p_value_desc>This 1-sided p-value should be compared to the 1-sided threshold of 0.0125 for non-inferiority. Due to the pre-specified hierarchial approach, further confirmatory analysis on the Week24 endpoints is only applicable if superiority is already met.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline at Week 52</title>
        <description>This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>This population includes the FAS further restricted to patients with a baseline body weight and one on-treatment body weight measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline at Week 52</title>
          <description>This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.</description>
          <population>This population includes the FAS further restricted to patients with a baseline body weight and one on-treatment body weight measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="722"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="0.13"/>
                    <measurement group_id="O2" value="1.38" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This Week52 key secondary endpoint was only to be tested (2-sided threshold of 0.025 to allow for multiple testing within a visit) if the Week52 primary hypothesis was rejected.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>-2.91</ci_lower_limit>
            <ci_upper_limit>-2.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline at Week 104</title>
        <description>This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.</description>
        <time_frame>Baseline and week 104</time_frame>
        <population>This population includes the FAS further restricted to patients with a baseline body weight and one on-treatment body weight measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline at Week 104</title>
          <description>This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.</description>
          <population>This population includes the FAS further restricted to patients with a baseline body weight and one on-treatment body weight measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="722"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="0.16"/>
                    <measurement group_id="O2" value="1.29" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Due to testing of multiple endpoints within a visit a sequential testing strategy (at 2-sided threshold of 0.025) was applied to the key secondary endpoints.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>-2.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycaemic Events up to 52 Weeks</title>
        <description>A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L)</description>
        <time_frame>Week 52</time_frame>
        <population>The treated set consisted of all patients treated with at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycaemic Events up to 52 Weeks</title>
          <description>A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L)</description>
          <population>The treated set consisted of all patients treated with at least one dose of study drug</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="776"/>
                <count group_id="O2" value="775"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This key secondary endpoint was only to be tested (comparing to a 2-sided threshold of 0.025) if the Week52 body weight change from baseline was confirmatory.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycaemic Events up to 104 Weeks</title>
        <description>A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L)</description>
        <time_frame>Week 104</time_frame>
        <population>The treated set consisted of all patients treated with at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycaemic Events up to 104 Weeks</title>
          <description>A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L)</description>
          <population>The treated set consisted of all patients treated with at least one dose of study drug</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="776"/>
                <count group_id="O2" value="775"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Due to testing of multiple endpoints within a visit a sequential testing strategy (at 2-sided threshold of 0.025) was applied to the key secondary endpoints.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline at Week 52</title>
        <description>This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications.</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>This population includes the FAS further restricted to patients with a baseline FPG and one on-treatment FPG measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline at Week 52</title>
          <description>This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications.</description>
          <population>This population includes the FAS further restricted to patients with a baseline FPG and one on-treatment FPG measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="725"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.40" spread="1.25"/>
                    <measurement group_id="O2" value="-15.24" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>6.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.51</ci_lower_limit>
            <ci_upper_limit>10.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline at Week 104</title>
        <description>This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications.</description>
        <time_frame>Baseline and week 104</time_frame>
        <population>This population includes the FAS further restricted to patients with a baseline FPG and one on-treatment FPG measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline at Week 104</title>
          <description>This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications.</description>
          <population>This population includes the FAS further restricted to patients with a baseline FPG and one on-treatment FPG measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="733"/>
                <count group_id="O2" value="725"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="1.46"/>
                    <measurement group_id="O2" value="-8.72" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>6.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.51</ci_lower_limit>
            <ci_upper_limit>10.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7.0% at Week 52</title>
        <description>The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c &gt;= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c &gt;= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=7.0%.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7.0% at Week 52</title>
          <description>The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c &gt;= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c &gt;= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
          <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=7.0%.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds ratio is treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.625</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.482</ci_lower_limit>
            <ci_upper_limit>0.811</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7.0% at Week 104</title>
        <description>The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c &gt;= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c &gt;= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
        <time_frame>Week 104</time_frame>
        <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=7.0%.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7.0% at Week 104</title>
          <description>The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c &gt;= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c &gt;= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
          <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=7.0%.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="591"/>
                <count group_id="O2" value="593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds ratio is treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.654</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.494</ci_lower_limit>
            <ci_upper_limit>0.866</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;6.5% at Week 52</title>
        <description>The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c &gt;= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c &gt;= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
        <time_frame>Week 52</time_frame>
        <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=6.5%.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;6.5% at Week 52</title>
          <description>The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c &gt;= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c &gt;= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
          <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=6.5%.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="738"/>
                <count group_id="O2" value="740"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds ratio is treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.648</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.489</ci_lower_limit>
            <ci_upper_limit>0.859</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;6.5% at Week 104</title>
        <description>The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c &gt;= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c &gt;= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
        <time_frame>Week 104</time_frame>
        <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=6.5%.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;6.5% at Week 104</title>
          <description>The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c &gt;= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c &gt;= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.</description>
          <population>Full analysis set (FAS) patients with non-completers considered as failures (i.e., non-responders) (NCF) and with baseline HbA1c &gt;=6.5%.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="736"/>
                <count group_id="O2" value="734"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0240</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds ratio is treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.689</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.498</ci_lower_limit>
            <ci_upper_limit>0.952</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c Lowering by 0.5% at Week 104</title>
        <description>Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104</description>
        <time_frame>Week 104</time_frame>
        <population>FAS (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c Lowering by 0.5% at Week 104</title>
          <description>Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104</description>
          <population>FAS (NCF)</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds ratio is treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.700</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.560</ci_lower_limit>
            <ci_upper_limit>0.875</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104</title>
        <description>This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications.</description>
        <time_frame>Baseline and week 104</time_frame>
        <population>Patients in the FAS with a valid meal tolerance test (MTT) at baseline and at least one valid on-treatment MTT (MTT104).</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104</title>
          <description>This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications.</description>
          <population>Patients in the FAS with a valid meal tolerance test (MTT) at baseline and at least one valid on-treatment MTT (MTT104).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.47" spread="4.32"/>
                    <measurement group_id="O2" value="-18.72" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linagliptin versus Glimepiride</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0918</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-9.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.07</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 4</title>
        <description>Difference of base percent value [Week x(%) - baseline (%)]</description>
        <time_frame>Baseline and week 4</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 4</title>
          <description>Difference of base percent value [Week x(%) - baseline (%)]</description>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.41"/>
                    <measurement group_id="O2" value="-0.33" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 8</title>
        <time_frame>Baseline and week 8</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 8</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.59"/>
                    <measurement group_id="O2" value="-0.58" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 12</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 12</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.64"/>
                    <measurement group_id="O2" value="-0.75" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 16</title>
        <time_frame>Baseline and week 16</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 16</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.66"/>
                    <measurement group_id="O2" value="-0.78" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 28</title>
        <time_frame>Baseline and week 28</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 28</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.73"/>
                    <measurement group_id="O2" value="-0.74" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 40</title>
        <time_frame>Baseline and week 40</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 40</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.77"/>
                    <measurement group_id="O2" value="-0.69" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 52</title>
        <time_frame>Baseline and week 52</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 52</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.82"/>
                    <measurement group_id="O2" value="-0.63" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 65</title>
        <time_frame>Baseline and week 65</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 65</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.91"/>
                    <measurement group_id="O2" value="-0.53" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 78</title>
        <time_frame>Baseline and week 78</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 78</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.92"/>
                    <measurement group_id="O2" value="-0.43" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 91</title>
        <time_frame>Baseline and week 91</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 91</title>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.94"/>
                    <measurement group_id="O2" value="-0.43" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change at Week 104</title>
        <description>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule.</description>
        <time_frame>Baseline and week 104</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change at Week 104</title>
          <description>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement. Last observation carried forward (LOCF) was used as imputation rule.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="764"/>
                <count group_id="O2" value="755"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.95"/>
                    <measurement group_id="O2" value="-0.41" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Lipid Parameter Cholesterol at Week 104</title>
        <time_frame>Baseline and week 104</time_frame>
        <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Lipid Parameter Cholesterol at Week 104</title>
          <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="741"/>
                <count group_id="O2" value="726"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="14"/>
                    <measurement group_id="O2" value="1" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Lipid Parameter HDL at Week 104</title>
        <time_frame>Baseline and week 104</time_frame>
        <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Lipid Parameter HDL at Week 104</title>
          <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="740"/>
                <count group_id="O2" value="725"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="9"/>
                    <measurement group_id="O2" value="0" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104</title>
        <time_frame>Baseline and week 104</time_frame>
        <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104</title>
          <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="734"/>
                <count group_id="O2" value="720"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="23"/>
                    <measurement group_id="O2" value="3" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Baseline Lipid Parameter Triglyceride at Week 104</title>
        <time_frame>Baseline and week 104</time_frame>
        <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin</title>
            <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline Lipid Parameter Triglyceride at Week 104</title>
          <population>This population includes the treated set (all patients treated with at least one dose of study drug), and non-missing laboratory data.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="740"/>
                <count group_id="O2" value="725"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="153"/>
                    <measurement group_id="O2" value="-7" spread="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day of first dose until 7 days after last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin</title>
          <description>Patients randomized to receive Linagliptin 5mg and metformin</description>
        </group>
        <group group_id="E2">
          <title>Glimepiride</title>
          <description>Patients randomized to receive Glimepiride 1-4mg and metformin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Mitral valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system dermoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Optic disc haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Rectal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Femoral nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign muscle neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Osteoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agnosia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Penile curvature</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Vaginal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypertrophic scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="438" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="526" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="267" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="775"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="776"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="775"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>With the exception of HbA1c&lt;6.5% and HbA1c&lt;7.0% at Week52, all other endpoints are presented in the Week52 repeated analysis within the final clinical trial report, where discrepancies between interim and final results are also explained.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

